Clinical Learning
Clinical 5: Venous thromboembolism – prevention, diagnosis and early management
Practical VTE risk assessment, hospital prophylaxis principles, and NICE diagnostic pathways for suspected DVT and pulmonary embolism.
Clinical safety: Use current guidance, local policy and patient-specific judgement.
Learning objectives
• Distinguish VTE prevention from diagnostic/treatment pathways • Apply structured hospital VTE and bleeding risk assessment principles • Use Wells-based pathways appropriately when DVT or PE is suspected • Understand when interim anticoagulation may be required • Recognise the need for current dosing, renal and bleeding-risk guidance
Clinical safety note
Anticoagulation can cause serious harm. This module intentionally avoids reproducing dose tables. Use current NICE, BNF/MHRA and local anticoagulation guidance, confirm renal function and bleeding risk, and obtain senior/specialist advice where appropriate.
Two related clinical questions
VTE care involves two distinct questions. First: how should hospital-acquired VTE be prevented? NICE NG89 addresses risk assessment and prophylaxis. Second: what should happen when DVT or PE is suspected or confirmed? NICE NG158 provides diagnostic and treatment pathways. Keeping these questions separate helps avoid confusing prophylactic and therapeutic anticoagulation.
Hospital VTE prevention
Assess VTE risk and bleeding risk in line with local implementation of NICE NG89. Reassess when the clinical condition changes. Decisions about pharmacological or mechanical prophylaxis depend on admission type, mobility, bleeding risk, renal function and other factors. Exact agents and doses should come from current local prescribing guidance and the BNF.
Suspected DVT and PE
For suspected DVT, NICE NG158 uses the 2-level DVT Wells score to estimate clinical probability and directs ultrasound/D-dimer testing accordingly. For suspected PE, use the 2-level PE Wells score and the relevant imaging/D-dimer pathway. When required investigations cannot be completed promptly, the guideline describes circumstances for interim therapeutic anticoagulation while awaiting definitive testing.
Confirmed VTE and safety
Confirmed proximal DVT or PE generally requires anticoagulation treatment, with drug choice influenced by renal function, cancer, antiphospholipid syndrome, body weight, bleeding risk, contraindications and patient preference. Because anticoagulant recommendations and product information can change, this module deliberately does not reproduce dose tables. Check the current guideline, BNF, MHRA advice and local anticoagulation service guidance.
